Premises: 1. Ledger flat, two former positions closed by operator; no open thesis needs an exit adjustment. 2. Issuer bookings predate Sep5; FRO warns ballast lowers realized rates; STNG Q2 describes fleet repositioning and lower exports reversing initial rate spike. 3. Skuld March warcover terms are not September premiums or proof these issuers lack cover. 4. Independent Sept5 losttonnage/fixtures unavailable in reviewed sources. FRO strongest bear: long-run trade normalization or cargo destruction reduces spot utilization and asset values; booked days limit incremental Q3 repricing. And then what: fewer cargoes offset longer routes; then renewal rates/cash flow weaken; then dividends and NAV support fade. STNG strongest bear: crude escalation need not improve product cargo availability, and contracted fleet/sales constrain spot upside. And then what: product shipments fall or repositioning completes; then uncovered days earn lower rates while operating costs persist; then charter renewals and valuation fall. Counterargument for both: rerouting and inventory replenishment sustain high rents. Both can be partly right across different voyage periods; no causal mapping from strikecount to EPS. Valid conditional chains, not predictions. Existing FRO test59 CI[-.8744,1.9585]% and STNG training-34.7095% remain controlling. Zero notional. Sources https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ ; https://www.scorpiotankers.com/scorpio-tankers-inc-announces-financial-results-for-the-second-quarter-of-2026-and-the-declaration-of-a-dividend/ ; https://www.scorpiotankers.com/scorpio-tankers-inc-announces-updates-on-third-quarter-2026-tce-rates-and-time-charter-out-agreements/ ; insurer and incident observations2885–86.
open_positions0
proposed_notional0
FRO_uncovered_VLCC_pct14
STNG_uncovered_LR2_pct15
FRO_prior_mean_CI_low-0.87
FRO_prior_mean_CI_high1.96
September 5 tanker incident: new primary event, unmeasured stock payoff
Premises: 1. CENTCOM Sept5 statement records a claimed physical incident (new observation); independent commercial damage/tonnage data absent. 2. Prior issuer review and tests59/48 remain controlling: booked TCE is not full-quarter realized earnings; ballast, contract exposure and offhire matter. 3. No new company deployment, freight fixture, insurance or throughput series establishes incremental net rents. First order scenario: lost usable shipping capacity or avoidance could tighten transport supply. Second order: compliant owners may receive rerouting demand, but reduced cargo exports and insurance/offhire costs could offset rate gains. Third order: persistent costs could alter sourcing and demand; normalization could reverse premiums. These are conditional mechanisms, not observed outcomes or political judgments. Strongest counterargument: historical FRO trend plus fresh incident may precede price repricing; counterexample is rising quoted rates with falling transported volume or uninsured loss. Binding constraint is quantified net executable edge, not incident salience. One military origin plus media copies does not establish independent corroboration. No new return probability assigned. Sources: https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4591744/centcom-destroys-3-irgc-oil-tankers-after-iran-targets-2-us-navy-warships/ ; https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ ; https://www.sec.gov/Archives/edgar/data/913290/000162828026021774/fro-20251231.htm . Prior issuer content read in recorded research, not refetched today.
claimed_vessels3
new_commercial_rate_observations0
authorized_notional0
Liquidity withdrawal can raise gross reversal returns while making them harder to earn
Start278.67cash; goal repeatable net gains; binding constraint is measured executable edge. Physical chain: (1) authorized imported lean can supplement domestic fatty trimmings and pressure grinding input prices; (2) contracts, freight, quota access and buyer concentration divide savings among exporter/importer/grinder/retailer; (3) if consumer prices fall, substitution demand and breeding incentives may change, while limited live-cattle availability can still constrain slaughter plants. Opposite chain: inspections, diversion from existing buyers or quota termination limit incremental supply, so scarcity persists. Neither chain is a probability forecast. Who benefits conditionally: eligible producers and import distributors with deliverable stock/market access, grinders with retained savings, consumers if passed through. Who bears risk: cull-cow sellers, suppliers without access, fixed-cost slaughter plants, poultry sellers if price competition increases. USDA Sep4 report endsAug29, hence cannot confirm newquota execution; top57520mt is allmeat, freshbeef38291mt. Monthly100000mt implies23333mt/week equivalent but is not actualadditionalflow. PlattsSep1 FCA3.03 down.25 (-7.62%) is an assessment without reported trades, not25%realizeddiscount. Sources https://www.ams.usda.gov/mnreports/lswimpe.pdf ; https://www.spglobal.com/energy/en/news-research/latest-news/agriculture/090126-brazil-origin-beef-offer-levels-into-us-drop-at-start-of-tariff-free-period ; observation1665policy. Strongest counterargument: tariff savings could improve exporters despite lower offers. Plausible, but unknown landed costs/allocations and mixed corporate exposure prevent quantified stock edge. Capacity grants do not supply cattle; no newfund justified.
weekly_quota_equivalent_mt23333.33
prequota_fresh_import_mt38291
FCA_assessed_drop_pct7.62
actual_quota_fillunknown
allocation0
Three-step catalyst chains and who benefits: dates alone do not create returns
Start49.14cash, goal repeatable net gains, binding constraint positive executable conditional payoff. GRAL: first a favorable panel could reduce regulatory uncertainty; second coverage/reimbursement and diagnostic workup capacity determine adoption; third sustained cash economics depend on pricing, test utilization and follow-up burden. A panel vote alone does not establish mortality benefit or reimbursement. Counterchain poor utility interpretation -> restrictive labeling or delay -> further funding needs. SRRK: manufacturing concern -> alternate-facility review across jurisdictions -> delayed commercial cash generation; suppliers with compliant capacity gain bargaining power, but this does not validate a supplier-stock trade. TLX: Pixclara decision -> possible commercial launch spending/revenue -> reimbursement and distribution determine profit; absent Pixclara from guidance prevents treating baseline forecasts as launch revenue. ORCL: committed cloud orders -> heavy buildout and customer concentration -> utilization/financing determine return on capital; chip, power and construction suppliers may receive revenue before Oracle earns cash return. Inditex: calendar-assisted growth -> inventory/markdown decisions -> margins and cash conversion, not constant-currency headline alone. CPRT: auction activity and recovery values -> fees/gross profit -> operating cash; a CEO transition may alter expectations, not known intrinsic value by itself. These are hypotheses from primary disclosures, not quantified forecasts or new fund cases. Strong counterargument cash misses rallies; rebuttal is unknown/negative measured expectancy, not conviction that prices must fall. Spread recipients benefit from unvalidated turnover; conserving cash preserves ability to test new evidence. Sources fundamental106/109, observations323–326/1195–1198 with originalURLs; https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting ; https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ .
cash49.14
eligible_new_positions0
Three-step consequence chains and the strongest case against remaining in cash
Start state: Quant245.69 cash, no holdings or queued orders. Goal: repeatable net gains. Binding constraint: a validated strategy that fits the account's actual exits and weights. 1. Shared AI-capital-spending exposure could support SNDK, Korean memory and Taiwanese manufacturers; then greater orders benefit AEHR test capacity; then investor crowding can transmit a funding shock across apparently separate country holdings. This is a hypothesis grounded in issuer concentration/order observations, not a forecast. 2. If financing or demand weakens, NX customers can delay building orders; then pricing recovery may fail to offset volumes; then debt service and equity expectations can absorb cash despite the latest paydown. Counterexample: operational efficiencies and continued cash generation could offset the shock. 3. Adding tight range exits to monthly momentum realizes smaller gains and earlier stop losses; then repeated two-sided costs reduce expectancy; then funding pressure may tempt more turnover. The measured +113.29% monthly versus +2.47% range holdout, and -28.12% cost stress, quantify why that transformation cannot be assumed harmless. Who benefits: issuers from assets under management, exchanges/liquidity providers from turnover, genuine capacity suppliers from delivered orders. Strongest counterargument to cash: monthly net evidence is positive and the account may miss a further rally. Rebuttal is limited: cash has opportunity cost, but the monthly strategy is not yet implementable as tested and its appropriate country benchmark returned101.80% with lower drawdown. No claim equities must fall. Facts: recorded historical prices, trials and primary releases; assumptions: future demand, crowding, normalization and resampled stationarity. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://www.ishares.com/us/literature/fact-sheet/ewy-ishares-msci-south-korea-etf-fund-fact-sheet-en-us.pdf ; https://www.ishares.com/us/literature/fact-sheet/ewt-ishares-msci-taiwan-etf-fund-fact-sheet-en-us.pdf ; issuer URLs in fundamental93. New daily research collector retains fixed ranks and eligible=0; no between-run trading is authorized.
cash245.69
monthly range return gap110.81
EWY EWT correlation0.76
proposed size0
Who captures the constraint: powered capacity, financing and freight
Start state278.67cash, no open or queued holdings; goalrepeatable net profit. Binding constraint is independently validated executable edge, not access to trading hours. Premise1: scarce powered racks can benefit IREN, but contracted4bn ARR versus1bn operating ARR is a commissioning gap, not4bn current annual recognized revenue. FY26netloss702.6m includes638.8m impairments; equipment suppliers can raise prices without corresponding customer pass-through and delayed deployment can reduce payments. First order: GPU/power/cooling costs and9%financing consume future rental revenue; second: delivery slippage or customerdefault stretches cash and converts contracts into penalties/credits; third: new capacity or fasterhardware obsolescence can erode returns before debt retires. Strong counterargument: prepayments and6%Microsoft-backedfinancing cover most GPUcapital; still not all site costs or utilization. Illustrative fully drawn interest3.6bn*6%+2.4bn*9%=432m/year, not reportedforecast. Source https://www.sec.gov/Archives/edgar/data/1878848/000187884826000051/irenreportsfy26results.htm . Premise2: Render fiat-priced jobs burn tokens while scheduled emissions reward operators. First: users buy compute; second: operators' reward/cost balance changes supply; third: token returns depend on matched burns/emissions and valuation rather than GPUscarcity alone. Cumulative1.532m burn andYear2emissions5.906m coverdifferentperiods; reject false deflation ratio. Sources https://know.rendernetwork.com/basics/burn-mint-equilibrium ; https://stats.renderfoundation.com/ . Premise3: Maersk realized higherfreight rates benefits scarce vesselspace but shippers pay; then inventory workingcapital and productmargins suffer; then rerouting/newvessels/demanddestruction can normalize rent. Supplier ETN/PSIX similarly may both benefit downstream and pay upstream constraints. Countercase sustained demand and successful commissioning can sustain margins, but no stockpayoff follows logically without valuation and tested timing. Source https://www.maersk.com/news/articles/2026/08/13/maersk-delivers-strong-q2-and-raises-full-year-guidance . Facts are datedissuerdisclosures; chains are hypotheses, not forecasts. No distinct newfund justified: physicalcompute fitsSupply and majors belongexistingCrypto.
IREN_contracted_ARR_bn4
IREN_operating_ARR_bn1
IREN_interest_illustration_m432
RENDER_cumulative_burn1531871
RENDER_Year2_emission_budget5905580
eligible0
Token utility versus token demand: attack the expanded shortlist
Start state0holdings/0queued, goal repeatable net returns; binding constraint validated payoff after costs, not crypto trading hours. No existing stops/targets to change. BTC strongest bear case: failed closing breakout plus unverified fresh ETF creations. And then1: chasing yesterday's signal incurs two-sided costs;2: reversal consumes an uncalibrated stop budget;3: correlated ETH/SOL replacement risk compounds losses. Counterargument: ETF demand and momentum could revive, but neither is calibrated current edge. ETH bear case: upgrade repricing changes may disrupt a subset of contracts. Then1: builders must alter gas assumptions;2: implementation delays or higher state-operation cost can slow some activity;3: token returns still depend on adoption, issuance/burn and valuation, not throughput alone. Counterargument: most contracts unaffected, fixes and capacity expansion may improve adoption. SOL bear case: Q3 versusOctober date conflict and current close below109.15 trigger. Then1: anticipated launch demand may precede actual activation;2: delay/rollout risk can reverse positioning;3: limitedN12 price-rule calibration and BTC beta1.20 amplify sizing error. Counterargument: successful150ms-finality target could improve applications; cannot translate that engineering target into investment payoff. Who benefits: users/builders from successful capacity; liquidity providers collect spread/fees on premature turnover; exchange perpetual funding paid between leveraged parties is not income for this spot book. Attack cash: missing a rally is opportunity cost, but a funding deadline changes incentives, not conditional expectancy. Current evidence supports0risk, not assertion majors must fall. Facts end at recorded prices, tests, issuer schedules; economic chains are hypotheses. Sources https://runway.adityaperswal.workers.dev/data/crypto-bars ; https://www.ishares.com/us/products/333011/ishares-bitcoin-trust-etf ; https://blog.ethereum.org/2026/08/24/glamsterdam-repricing-testing ; https://solana.com/upgrades ; https://solana.com/upgrades/alpenglow .
open holdings0
new positions0
fund cash235.86
current due actions0
Attack former tanker book: scarcity is not monotonic equity upside
No open holdings or queued orders; no stops/targets to adjust. Strongest FRO bear: normalization releases vessel capacity, while prolonged disruption can destroy cargo and raise uninsured/off-hire costs; both directions can hurt the naive more-war-more-profit thesis. (1) Realized load-to-discharge revenue excludes ballast. (2) Lower effective earnings plus delivery commitments can reduce distributable cash. (3) Lower expected distributions and vessel values can compress equity before guidance. Counterexample: stockpile rebuilding/longer Atlantic routes and fixed charters could sustain earnings; this prevents a categorical short thesis. Newly read full attachment shows one charter explicitly stepping110k/70k/45k over three years, limiting that ship's upside without proving spot collapse. Strongest STNG bear: new fixed contracts trade upside for certainty; their two LR2 rates average41344/day versus64900 current spot/pool, a36.3% discount across different durations. (1) Locked revenue cushions spot weakness but caps those ships. (2) Product-volume contraction/counterparty risk can offset rerouting gains. (3) Fleet growth and lower marginal freight can reprice residual spot earnings. Counterexample: these are just2 of25 owned LR2s, not the entire fleet; guaranteed term income can increase value. Original diversification premise weakened by measured0.751 daily FRO/STNG correlation over420 OOS observations. Validity: these channels challenge monotonic pricing-power assumptions; they do not establish near-term negative returns. Soundness: issuer contracts direct, global orderbook estimates secondhand, no independent live cargo/war-insurance series. Sources: https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ ; https://ml-eu.globenewswire.com/Resource/Download/59431810-8e9c-4a39-b3d0-cc2dd63da402 ; https://www.sec.gov/Archives/edgar/data/913290/000162828026021774/fro-20251231.htm ; https://www.scorpiotankers.com/scorpio-tankers-inc-announces-updates-on-third-quarter-2026-tce-rates-and-time-charter-out-agreements/ ; https://runway.adityaperswal.workers.dev/data/stock-bars . Issuer dates Aug28/Sep3, filings FY2025; not new Sep4 announcements. What changed Sep4: both IEX closes crossed prior20 closing highs, but price strength does not resolve implementation/uncertainty. Start cash, goal repeatable returns, binding constraint robust tested payoff distribution.
open_positions0
FRO_charter_y1110000
FRO_charter_y345000
STNG_term_spot_ratio0.64
tanker_daily_correlation0.75
proposed_notional0
Attack the former biotech book: three-step adverse chains and strongest countercases
No holdings exist; these are replacement-thesis attacks, no exits or adjustments. RARE: Sept2 issuer confirms primary and secondary Aspire misses. First order lower expected GTX102 value; second possible expense reductions/change in resource allocation; third execution disruption and financing/valuation uncertainty can dominate UX111 run-up. Strongest countercase commercial medicines and potential UX111 value survive; failure of one asset does not scientifically invalidate another. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-aspire-results-angelman-syndrome . IONS: Sept4 issuer8K confirms pelacarsen outcomes failure despite biomarker lowering, today’s adverse change already reviewed in earlier run. First order reduced program revenue/royalty expectations; second Novartis must reassess development and resource commitments; third biomarker-to-outcome assumptions need re-evaluation, while launch/other pipeline economics determine residual equity value. Countercase approved zilganersen and other programs remain distinct; no hazard ratio/full results/valuation sensitivity means no quantified impairment claim. https://ir.ionispharma.com/static-files/a612d86f-2531-470a-9340-5e0db04932c9 . MIRM: primary p=.0986 and undated AZURE1 Q3 overlap. First order regulatory/readout surprise can arrive during run-up; second launch/royalty timing affects both Mirum and Incyte; third greater spend or delay alters equity funding needs despite growing commercial sales. Countercase secondary efficacy and rare-disease unmet need may support FDA judgment, but cannot supply a stock-return edge. https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx . Facts end at issuer disclosures; all transmission chains are qualitative hypotheses, not measured causal effects. Start49.14cash, goal reproducible net gains; binding constraints complete dated inventories, uncertain overlapping events, and numerical strategy edge. No new companywide IONS inventory completed; existing rejection remains. Regulatory outcomes benefit patients if successful, sponsors/partners commercially; unsupported turnover benefits liquidity providers. Zero size does not assert zero probability of rallies.
current holdings0
new proposal size0
RARE eventAspire failed September2
IONS eventpelacarsen failed September4
MIRM overlapAZURE1 Q3
Attack the former PEAD book: no live theses or exits to reset
September5 nightly attack, primary ledger query_trades fund=quant confirms all three lots closed September4 through operator liquidation; zero holdings, pending orders or monitors. 1. Strongest bear case against the former shared thesis: next-open purchase of a large positive earnings gap can select already-priced information and exhaustion, rather than residual drift. 2. Saved selected holdout #10 lost30.23% at20 sessions, N3; not rerun or independently audited because local /tmp and /app/agent filename search found no original artifacts. 3. DELL's+7.94% forced outcome cannot validate4-6week exits; GTLB-5.13% and SNOW-5.39% also reflect interrupted exits. Conclusion: old re-entry instructions stay superseded; no stops/targets exist to reset. Validity: absence of eligible tested edge implies zero policy size; soundness limited by tiny selected evidence and missing artifacts, not proof all PEAD fails. Per-thesis qualitative chain: GTLB large-gap expectations -> less residual upside if fully priced -> reversal may trigger costly forced exit; DELL favorable operational headline -> valuation may already capitalize demand -> supplier-margin or growth disappointment could reverse gains; SNOW favorable headline -> richer expectations -> execution shortfall could compress valuation. These are counterfactual stress paths, not newly verified company fundamentals. Today's change is book liquidation, not a newly measured fundamental deterioration. We do not claim a fresh issuer-news audit. Start cash245.69, goal reproducible edge, binding constraint independent net rule. Who benefits from unsupported re-entry: spread recipients. Source ledger and saved analysis#10, plus prior research source https://arxiv.org/abs/2601.08962 (not freshly reopened this run).
Premise 1: classic SUE-decile PEAD is cross-sectional and often long-short; this venue used adjusted-EPS beat + guidance + positive gap, long-only. Premise 2: Martineau finds large-cap PEAD absent since 2006. Premise 3: 2026 tick research finds ~70% of price discovery within five minutes and post-2016 BBO returns 0.01% before latency. Premise 4: our next-open screen lost 30.2% in the last-three holdout. Conclusion is valid if these evidence sets map to liquid US names; soundness is limited by our small selected sample and differing signal definitions. First order: next-open buyers receive the residual after most information is priced. Second order: selecting large gaps concentrates reversal/tail risk; one -20.8% five-day loss erased six winners. Third order: stops do not protect opening gaps and apparent 4-6 week PEAD exposure is mostly unvalidated idiosyncratic risk. Who benefits: fast after-hours liquidity providers and informed traders; late market buyers pay the discovery premium. Binding constraint is a pre-registered, broad OOS sample showing positive net next-open returns. Current GTLB/DELL/SNOW must liquidate under operator directive; do not re-enter from this thesis.
price discovery 5m70
post-2016 BBO0.01
holdout return-30.23
5d tail loss-20.76
current lots3
Overlapping and early catalysts defeat calendar-only exits
Start state: biotech run-ups were sized around one documented PDUFA with exit 3-4 days before. Binding constraint: issuers and FDA control timing, not the calendar. First order: RARE lost 45.9% when a separately disclosed Phase 3 readout arrived inside the holding window; IONS received approval 19 days early and fell 5.3%. Second order: stops cannot cap overnight gaps and positive decisions can sell off. Third order: every biotech position needs a company-wide catalyst map through exit plus early-action stress; undated windows inside the hold make size zero unless intentionally accepted. MIRM must liquidate under operator directive; no substitute entry.